Patch testing for allergic contact dermatitis in the pediatric population is performed at a higher rate than previously reported, but still grossly underreported, according to a study of the Pediatric Contact Dermatitis Registry.
Ingredients used in topical products used to relieve atopic dermatitis in children might put those patients at higher risk for contact dermatitis.
The April Table of the Month discusses diagnostic and therapeutic tips for AD patients.
Experts weigh in on what to know about the new addendum to the peanut allergy prevention guidelines.
Research aimed at understanding the host-microbial interface in atopic dermatitis is ongoing but already providing insights for novel therapeutic strategies.
The FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
This year has seen many advancements in pediatric dermatologic care spanning inflammatory conditions to skin cancer as well as the nuances of these conditions in skin of color patients. These are the top 5 pediatric articles of 2016 from Dermatology Times.
Exciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
Direct sequencing data, together with culture data, supplies researchers with information about communities of bacteria and fungi on the skin.
Researchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.